We are live on ! Find out more
CHRS icon

Coherus Oncology
CHRS

117 hedge funds and large institutions have $741M invested in Coherus Oncology in 2016 Q3 according to their latest regulatory filings, with 39 funds opening new positions, 40 increasing their positions, 23 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

388% more first-time investments, than exits

New positions opened: 39 | Existing positions closed: 8

100% more funds holding in top 10

Funds holding in top 10: 1 → 2 (+1)

74% more repeat investments, than reductions

Existing positions increased: 40 | Existing positions reduced: 23

73% more capital invested

Capital invested by funds: $428M → $741M (+$313M)

36% more funds holding

Funds holding: 86 → 117 (+31)

84% less call options, than puts

Call options by funds: $644K | Put options by funds: $3.99M

Holders
117
Holders Change
+31
Holders Change %
+36.05%
% of All Funds
3.12%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.05%
New
39
Increased
40
Reduced
23
Closed
8
Calls
$644K
Puts
$3.99M
Net Calls
-$3.35M
Net Calls Change
-$2.94M

Top Buyers

Rank Fund Capital Flow
1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$22.7M
2
O
OrbiMed
New York
+$18.3M
3
Millennium Management
Millennium Management
New York
+$16.5M
4
PAMU
Pictet Asset Management (UK)
United Kingdom
+$10.4M
5
BM
Bridger Management
New York
+$9.82M

Top Sellers

Rank Fund Capital Flow
1
Wellington Management Group
Wellington Management Group
Massachusetts
-$16.1M
2
Citadel Advisors
Citadel Advisors
Florida
-$15.2M
3
VM
VHCP Management
New York
-$8.33M
4
TCIM
TIAA CREF Investment Management
New York
-$7.13M
5
VMI
VHCP Management II
New York
-$3.54M
Name Holding Trade Value Shares
Change 		Change in
Stake
CS
26
Candriam SCA
Luxembourg
$5.12M +$5.21M +191,000 New
CS
27
Credit Suisse
Switzerland
$4.61M +$3.63M +133,249 +342%
CWG
28
C WorldWide Group
Denmark
$4.2M +$158K +5,800 +4%
TA
29
Teachers Advisors
New York
$3.89M -$23.6K -865 -0.6%
EAM
30
Eventide Asset Management
Massachusetts
$3.88M – – –
Allianz Asset Management
31
Allianz Asset Management
Germany
$3.74M +$2.62M +96,046 +208%
Bank of New York Mellon
32
Bank of New York Mellon
New York
$3.59M -$102K -3,730 -3%
RPAM
33
Rhenman & Partners Asset Management
Sweden
$3.52M – – –
VMI
34
VHCP Management II
New York
$3.47M -$3.54M -129,630 -50%
Citadel Advisors
35
Citadel Advisors
Florida
$3.19M -$15.2M -556,501 -82%
BIM
36
BlackRock Investment Management
Delaware
$3.11M +$54K +1,978 +2%
Charles Schwab
37
Charles Schwab
California
$3.05M +$204K +7,496 +7%
D.E. Shaw & Co
38
D.E. Shaw & Co
New York
$2.72M +$2.77M +101,673 New
LOAMS
39
Lombard Odier Asset Management (Switzerland)
Switzerland
$2.68M -$264K -9,664 -9%
SIM
40
Spark Investment Management
New York
$2.27M -$2.74M -100,500 -54%
BA
41
BlackRock Advisors
Delaware
$2.08M +$1.63M +59,626 +327%
SCM
42
Sio Capital Management
New York
$1.96M +$1.99M +73,053 New
HI
43
HBK Investments
Texas
$1.7M +$1.73M +63,500 New
California State Teachers Retirement System (CalSTRS)
44
California State Teachers Retirement System (CalSTRS)
California
$1.67M +$16.4K +600 +1%
Macquarie Group
45
Macquarie Group
Australia
$1.56M -$1.44M -52,855 -48%
Morgan Stanley
46
Morgan Stanley
New York
$1.52M +$1.5M +54,941 +2,844%
KCM
47
Kennedy Capital Management
Missouri
$1.47M +$1.5M +54,829 New
NI
48
Numeric Investors
Massachusetts
$1.47M +$1.49M +54,700 New
EA
49
Emerald Acquisition
Washington
$1.4M +$1.01M +37,134 +248%
TI
50
Turner Investments
Pennsylvania
$1.33M -$1.94M -71,290 -59%
1
2
3 4 5

CHRS Hedge Fund Activity: Q3 2016 in Review

117 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Coherus Oncology (CHRS) for Q3 2016, worth a combined $741M — up 73% from $428M a quarter earlier.

Buyers outnumbered sellers: 39 funds opened new CHRS positions and 8 closed out — a net gain of 31 holders — while 40 added to existing stakes and 23 trimmed.

The largest buyer was T. Rowe Price Associates, opening a new position worth an estimated $22.7M. The largest seller was Wellington Management Group, cutting an estimated $16.1M.

  • 117 institutional investors held Coherus Oncology (CHRS) as of Q3 2016, up from 86 in Q2 2016.
  • Funds reported $741M of Coherus Oncology stock for Q3 2016, up 73% quarter-over-quarter.
  • 39 funds opened new Coherus Oncology positions in Q3 2016 and 8 closed out, a net change of +31 holders.
  • The largest Coherus Oncology buyer in Q3 2016 was T. Rowe Price Associates, an estimated $22.7M added.
  • The largest Coherus Oncology seller in Q3 2016 was Wellington Management Group, an estimated $16.1M sold.

Based on aggregated 13F filings for Q3 2016.